BARD1 is building a portfolio of BARD1 Tests for the screening, diagnosis and monitoring of cancer to help save people’s lives. BARD1 currently has two BARD1 autoantibody tests in development for early detection of lung and ovarian cancers. BARD1 autoantibody tests measure multiple BARD1 autoantibodies in the blood and use a proprietary algorithm to combine these levels into a cancer score that identifies the presence or absence of a specific cancer. BARD1 also has a research-stage cancer vaccine project under evaluation for treatment of cancer.

Diagnostics Pipeline

Therapeutics Pipeline